Skip to main content

Gastroparesis clinical trials at UC Health
5 in progress, 3 open to eligible people

  • A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis 01

    open to eligible people ages 18 years and up

    This study will evaluate the safety and efficacy of Relamorelin compared to placebo in patients with diabetic gastroparesis. Patients will report daily severity scores of their diabetic gastroparesis symptoms.

    at UCSD

  • A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04

    open to eligible people ages 18 years and up

    A 52-week study to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG) with respect to the core signs and symptoms of diabetic gastroparesis.

    at UCSD

  • Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis

    open to eligible people ages 18-70

    This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States. One hundred fifty (150) subjects diagnosed with gastroparesis, who satisfy the selection criteria for the study, will be randomized to one of two treatment groups, active or placebo.

    at UCLA

  • A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03

    Sorry, accepting new patients by invitation only

    A 46-week study to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG). At the end of the 40-week Treatment Period, participants will either continue on relamorelin or placebo for 6 additional weeks.

    at UCSD

  • Diabetic Gastroparesis Study 05

    Sorry, not currently recruiting here

    This open-label study is to assess the safety of continued treatment with Relamorelin for participants who previously completed the RLM-MD-03 or RLM-MD-04 study and to provide treatment for these participants until Relamorelin becomes commercially available or the Sponsor terminates development.

    at UCSD

Last updated: